Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 264

1.
2.

Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.

Ray N, Harrison JE, Blackburn LA, Martin JN, Deeks SG, Doms RW.

J Virol. 2007 Apr;81(7):3240-50. Epub 2007 Jan 24.

3.

Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.

Labrosse B, Morand-Joubert L, Goubard A, Rochas S, Labernardière JL, Pacanowski J, Meynard JL, Hance AJ, Clavel F, Mammano F.

J Virol. 2006 Sep;80(17):8807-19.

4.

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.

Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, Pohlmann S, Sfakianos JN, Derdeyn CA, Blumenthal R, Hunter E, Doms RW.

Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54. Epub 2002 Nov 20.

5.
6.

Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates.

Baatz F, Nijhuis M, Lemaire M, Riedijk M, Wensing AM, Servais JY, van Ham PM, Hoepelman AI, Koopmans PP, Sprenger HG, Devaux C, Schmit JC, Perez Bercoff D.

PLoS One. 2011;6(7):e21535. doi: 10.1371/journal.pone.0021535. Epub 2011 Jul 8.

7.

Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).

Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR.

J Virol. 2004 May;78(9):4628-37.

8.

Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure.

Poveda E, Rodés B, Labernardière JL, Benito JM, Toro C, González-Lahoz J, Faudon JL, Clavel F, Schapiro J, Soriano V.

J Med Virol. 2004 Sep;74(1):21-8.

PMID:
15258964
9.

Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.

Mink M, Mosier SM, Janumpalli S, Davison D, Jin L, Melby T, Sista P, Erickson J, Lambert D, Stanfield-Oakley SA, Salgo M, Cammack N, Matthews T, Greenberg ML.

J Virol. 2005 Oct;79(19):12447-54.

10.
11.

Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.

Xu L, Pozniak A, Wildfire A, Stanfield-Oakley SA, Mosier SM, Ratcliffe D, Workman J, Joall A, Myers R, Smit E, Cane PA, Greenberg ML, Pillay D.

Antimicrob Agents Chemother. 2005 Mar;49(3):1113-9.

12.

Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev.

Svicher V, Alteri C, D'Arrigo R, Laganà A, Trignetti M, Lo Caputo S, Callegaro AP, Maggiolo F, Mazzotta F, Ferro A, Dimonte S, Aquaro S, di Perri G, Bonora S, Tommasi C, Trotta MP, Narciso P, Antinori A, Perno CF, Ceccherini-Silberstein F.

Antimicrob Agents Chemother. 2009 Jul;53(7):2816-23. doi: 10.1128/AAC.01067-08. Epub 2009 Jan 5.

13.

Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity.

Reeves JD, Miamidian JL, Biscone MJ, Lee FH, Ahmad N, Pierson TC, Doms RW.

J Virol. 2004 May;78(10):5476-85.

14.

Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and six-helix bundle structure.

Bai X, Wilson KL, Seedorff JE, Ahrens D, Green J, Davison DK, Jin L, Stanfield-Oakley SA, Mosier SM, Melby TE, Cammack N, Wang Z, Greenberg ML, Dwyer JJ.

Biochemistry. 2008 Jun 24;47(25):6662-70. doi: 10.1021/bi702509d.

PMID:
18507398
15.

Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01_AE env gene derived from HIV-1-infected patient, residing in central Thailand.

Utachee P, Jinnopat P, Isarangkura-Na-Ayuthaya P, de Silva UC, Nakamura S, Siripanyaphinyo U, Wichukchinda N, Tokunaga K, Yasunaga T, Sawanpanyalert P, Ikuta K, Auwanit W, Kameoka M.

Microbes Infect. 2009 Mar;11(3):334-43. doi: 10.1016/j.micinf.2008.12.008. Epub 2008 Dec 27.

PMID:
19136072
16.

HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications.

Miller MD, Hazuda DJ.

Drug Resist Updat. 2004 Apr;7(2):89-95.

PMID:
15158765
17.
18.

Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy.

Charpentier C, Jenabian MA, Piketty C, Karmochkine M, Tisserand P, Laureillard D, Bélec L, Si-Mohamed A, Weiss L.

Scand J Infect Dis. 2011 May;43(5):373-9. doi: 10.3109/00365548.2011.552520. Epub 2011 Feb 22.

PMID:
21341978
19.

The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype.

Cunyat F, Marfil S, García E, Svicher V, Pérez-Alvárez N, Curriu M, Perno CF, Clotet B, Blanco J, Cabrera C.

Retrovirology. 2012 Feb 14;9:15. doi: 10.1186/1742-4690-9-15.

20.

Functional impact of HIV coreceptor-binding site mutations.

Biscone MJ, Miamidian JL, Muchiri JM, Baik SS, Lee FH, Doms RW, Reeves JD.

Virology. 2006 Jul 20;351(1):226-36. Epub 2006 Apr 21.

Supplemental Content

Support Center